Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals
Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
NZK | Ann: NZK 1HY25 Half Year Results | 24/09/24 | 0 | 45 | |||
|
|||||||
NZK | Ann: NZK 1HY25 Half Year Results Announcement Details | 02/09/24 | 0 | 75 | |||
|
|||||||
NZK | Ann: Change of External Auditor | 02/07/24 | 0 | 118 | |||
|
|||||||
NZK | Ann: Grant of Performance Share Rights | 01/07/24 | 0 | 84 | |||
|
|||||||
NZK | Ann: NZK - 2024 Annual Shareholder Meeting Results | 19/06/24 | 0 | 107 | |||
|
|||||||
NZK | Ann: ASM Meeting Materials | 19/06/24 | 0 | 143 | |||
|
|||||||
NZK | Ann: Climate-Related Disclosures FY24 | 29/05/24 | 0 | 115 | |||
|
|||||||
NZK | Ann: Notice of Annual Shareholders Meeting | 20/05/24 | 0 | 118 | |||
|
See All Discussions